| Mrs Heather J Hastings, CRNA | |
|
1900 Kildaire Farm Rd, Cary, NC 27518-6616 | |
| (919) 350-8000 | |
| Not Available |
| Full Name | Mrs Heather J Hastings |
|---|---|
| Gender | Female |
| Speciality | Nurse Anesthetist, Certified Registered |
| Location | 1900 Kildaire Farm Rd, Cary, North Carolina |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962703751 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 76578 (Connecticut) | Secondary |
| 367500000X | Nurse Anesthetist, Certified Registered | 85143 (North Carolina) | Primary |
| Entity Name | University Of North Carolina At Chapel Hill |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780669200 PECOS PAC ID: 0648181156 Enrollment ID: O20031105000359 |
News Archive
A new drug to treat hepatitis C that costs $1,000 a pill has caused rising concern among insurers and state Medicaid programs. It has now also spurred interest from Democratic congressmen whose queries about the drug prompted a sell-off in biotechnology stocks on Friday. Three Democratic members of the House Energy and Commerce Committee have demanded that Gilead Sciences, the developer, justify the price of its drug, which is called Sovaldi (Pollack, 3/21).
This episode turns the tables: Host Dan Weissmann gets interviewed about what he learned in 2020 and what's ahead for the show — with T.K. Dutes, a radio host and podcast-maker who is also a former nurse, so she knows a thing or two about the health care system.
About one in ten people in southern India is diabetic. Around one in three suffers from a so-called diabetic retinopathy (DR), a disease of the retina caused by diabetes.
Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE).
› Verified 2 days ago
| Entity Name | American Anesthesiology Of North Carolina Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053677195 PECOS PAC ID: 2961316450 Enrollment ID: O20031229000004 |
News Archive
A new drug to treat hepatitis C that costs $1,000 a pill has caused rising concern among insurers and state Medicaid programs. It has now also spurred interest from Democratic congressmen whose queries about the drug prompted a sell-off in biotechnology stocks on Friday. Three Democratic members of the House Energy and Commerce Committee have demanded that Gilead Sciences, the developer, justify the price of its drug, which is called Sovaldi (Pollack, 3/21).
This episode turns the tables: Host Dan Weissmann gets interviewed about what he learned in 2020 and what's ahead for the show — with T.K. Dutes, a radio host and podcast-maker who is also a former nurse, so she knows a thing or two about the health care system.
About one in ten people in southern India is diabetic. Around one in three suffers from a so-called diabetic retinopathy (DR), a disease of the retina caused by diabetes.
Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE).
› Verified 2 days ago
| Entity Name | East Carolina Anesthesia Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205996519 PECOS PAC ID: 5092720813 Enrollment ID: O20060215000791 |
News Archive
A new drug to treat hepatitis C that costs $1,000 a pill has caused rising concern among insurers and state Medicaid programs. It has now also spurred interest from Democratic congressmen whose queries about the drug prompted a sell-off in biotechnology stocks on Friday. Three Democratic members of the House Energy and Commerce Committee have demanded that Gilead Sciences, the developer, justify the price of its drug, which is called Sovaldi (Pollack, 3/21).
This episode turns the tables: Host Dan Weissmann gets interviewed about what he learned in 2020 and what's ahead for the show — with T.K. Dutes, a radio host and podcast-maker who is also a former nurse, so she knows a thing or two about the health care system.
About one in ten people in southern India is diabetic. Around one in three suffers from a so-called diabetic retinopathy (DR), a disease of the retina caused by diabetes.
Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE).
› Verified 2 days ago
| Entity Name | Chatham Hospital Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1093712655 PECOS PAC ID: 5991604902 Enrollment ID: O20061104000243 |
News Archive
A new drug to treat hepatitis C that costs $1,000 a pill has caused rising concern among insurers and state Medicaid programs. It has now also spurred interest from Democratic congressmen whose queries about the drug prompted a sell-off in biotechnology stocks on Friday. Three Democratic members of the House Energy and Commerce Committee have demanded that Gilead Sciences, the developer, justify the price of its drug, which is called Sovaldi (Pollack, 3/21).
This episode turns the tables: Host Dan Weissmann gets interviewed about what he learned in 2020 and what's ahead for the show — with T.K. Dutes, a radio host and podcast-maker who is also a former nurse, so she knows a thing or two about the health care system.
About one in ten people in southern India is diabetic. Around one in three suffers from a so-called diabetic retinopathy (DR), a disease of the retina caused by diabetes.
Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE).
› Verified 2 days ago
| Entity Name | Regional Anesthesia, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952486946 PECOS PAC ID: 3779681408 Enrollment ID: O20070604000698 |
News Archive
A new drug to treat hepatitis C that costs $1,000 a pill has caused rising concern among insurers and state Medicaid programs. It has now also spurred interest from Democratic congressmen whose queries about the drug prompted a sell-off in biotechnology stocks on Friday. Three Democratic members of the House Energy and Commerce Committee have demanded that Gilead Sciences, the developer, justify the price of its drug, which is called Sovaldi (Pollack, 3/21).
This episode turns the tables: Host Dan Weissmann gets interviewed about what he learned in 2020 and what's ahead for the show — with T.K. Dutes, a radio host and podcast-maker who is also a former nurse, so she knows a thing or two about the health care system.
About one in ten people in southern India is diabetic. Around one in three suffers from a so-called diabetic retinopathy (DR), a disease of the retina caused by diabetes.
Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE).
› Verified 2 days ago
| Entity Name | Chatham Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689967457 PECOS PAC ID: 4284807868 Enrollment ID: O20111026000545 |
News Archive
A new drug to treat hepatitis C that costs $1,000 a pill has caused rising concern among insurers and state Medicaid programs. It has now also spurred interest from Democratic congressmen whose queries about the drug prompted a sell-off in biotechnology stocks on Friday. Three Democratic members of the House Energy and Commerce Committee have demanded that Gilead Sciences, the developer, justify the price of its drug, which is called Sovaldi (Pollack, 3/21).
This episode turns the tables: Host Dan Weissmann gets interviewed about what he learned in 2020 and what's ahead for the show — with T.K. Dutes, a radio host and podcast-maker who is also a former nurse, so she knows a thing or two about the health care system.
About one in ten people in southern India is diabetic. Around one in three suffers from a so-called diabetic retinopathy (DR), a disease of the retina caused by diabetes.
Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE).
› Verified 2 days ago
| Entity Name | Duke Health Integrated Practice Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205553369 PECOS PAC ID: 8325412737 Enrollment ID: O20230327002247 |
News Archive
A new drug to treat hepatitis C that costs $1,000 a pill has caused rising concern among insurers and state Medicaid programs. It has now also spurred interest from Democratic congressmen whose queries about the drug prompted a sell-off in biotechnology stocks on Friday. Three Democratic members of the House Energy and Commerce Committee have demanded that Gilead Sciences, the developer, justify the price of its drug, which is called Sovaldi (Pollack, 3/21).
This episode turns the tables: Host Dan Weissmann gets interviewed about what he learned in 2020 and what's ahead for the show — with T.K. Dutes, a radio host and podcast-maker who is also a former nurse, so she knows a thing or two about the health care system.
About one in ten people in southern India is diabetic. Around one in three suffers from a so-called diabetic retinopathy (DR), a disease of the retina caused by diabetes.
Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Heather J Hastings, CRNA 3100 Spring Forest Rd, Suite 130, Raleigh, NC 27616-2880 Ph: (919) 882-0706 | Mrs Heather J Hastings, CRNA 1900 Kildaire Farm Rd, Cary, NC 27518-6616 Ph: (919) 350-8000 |
News Archive
A new drug to treat hepatitis C that costs $1,000 a pill has caused rising concern among insurers and state Medicaid programs. It has now also spurred interest from Democratic congressmen whose queries about the drug prompted a sell-off in biotechnology stocks on Friday. Three Democratic members of the House Energy and Commerce Committee have demanded that Gilead Sciences, the developer, justify the price of its drug, which is called Sovaldi (Pollack, 3/21).
This episode turns the tables: Host Dan Weissmann gets interviewed about what he learned in 2020 and what's ahead for the show — with T.K. Dutes, a radio host and podcast-maker who is also a former nurse, so she knows a thing or two about the health care system.
About one in ten people in southern India is diabetic. Around one in three suffers from a so-called diabetic retinopathy (DR), a disease of the retina caused by diabetes.
Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE).
› Verified 2 days ago
Linda Lee Erskine-bauer, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1900 Kildaire Farm Rd, Cary, NC 27518 Phone: 919-873-9533 | |
Mr. Richard Christopher Sabin, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1900 Kildaire Farm Rd, Cary, NC 27518 Phone: 919-350-8000 | |
Anne Marie Defranco Telford, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1900 Kildaire Farm Rd, Cary, NC 27518 Phone: 919-350-5645 | |
Ethan Hazelrigs, BSN, MSN, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 500 Heathridge Lane, Cary, NC 27513 Phone: 919-720-2723 | |
Joseph Rybicki, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 823 Carpenter Town Ln, Cary, NC 27519 Phone: 919-812-6514 | |
Mrs. Michelle Lee Weaver, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 105 Hedwig Ct, Cary, NC 27518 Phone: 919-362-4971 | |
Mrs. Angela Marie Marriner, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1900 Kildaire Farm Rd, Cary, NC 27518 Phone: 919-350-2330 |